Bringing the human touch to oncology
Cytogen Corporation has a product portfolio that’s tightly focused on oncology. Quadramet© is a targeted palliative therapy for painful bone metastases. Stringent regulatory requirements and physicians’ reluctance to prescribe a myelosuppressive agent to patients with compromised bone marrow combined to severely limit Quadramet© prescriptions.